Producing safe and highly effective anticancer therapies is only part of the new drug development equation, and ensuring patients’ access to them is equally, if not more, important for pharma companies operating in today’s environment.
As governments around the world, squeezed by ballooning medical expenditures, increase their scrutiny of drug prices, major manufacturers like